Cross-Market Price Comparison
| Other Listed Market | To be extracted |
|---|---|
| Other Market Stock Code | To be extracted |
| H-Share Offer Price | HK$ 648.00 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Zai Lab |
|---|---|
| Stock Code | 09688 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 創新型、立足研發及處於商業階段的生物製藥公司,專注於發現、授權、開發及商業化療法,解決中國及全球市場的巨大醫療需求缺口,包括腫瘤、抗感染及自體免疫性疾病領域。 |
| Listing Date | 2020-09-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東區金科路4560號1號樓4樓 |
| Business Address (Hong Kong) | 香港北角英皇道510號港運大廈23樓2301室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.zailaboratory.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | Yes (NASDAQ) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 648.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 50 shares |
| Entry Threshold | HK$ 32,400 |
| Par Value | To be extracted |
| Offer Period | 2020-09-17 to 2020-09-22 |
| Global Offering Shares | 10,564,050 shares |
| HK Public Offer Shares (Initial) | 771,700 shares (7.3%) |
| Public Offer Lots (Initial) | 15,434lots (Pool A7,717lots,Pool B7,717lots) |
| International Placing Shares (Initial) | 9,792,350 shares (92.7%) |
| Offer Ratio | ~7.3% |
| Total Shares Post-IPO | 85,939,561 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 6,845,504,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 50 | HK$ 32,400 |
| 2 lots | 100 | HK$ 64,800 |
| 3 lots | 150 | HK$ 97,200 |
| 4 lots | 200 | HK$ 129,600 |
| 5 lots | 250 | HK$ 162,000 |
| 6 lots | 300 | HK$ 194,400 |
| 7 lots | 350 | HK$ 226,800 |
| 8 lots | 400 | HK$ 259,200 |
| 9 lots | 450 | HK$ 291,600 |
| 10 lots | 500 | HK$ 324,000 |
| 12 lots | 600 | HK$ 388,800 |
| 14 lots | 700 | HK$ 453,600 |
| 16 lots | 800 | HK$ 518,400 |
| 18 lots | 900 | HK$ 583,200 |
| 20 lots | 1,000 | HK$ 648,000 |
| 30 lots | 1,500 | HK$ 972,000 |
| 40 lots | 2,000 | HK$ 1,296,000 |
| 50 lots | 2,500 | HK$ 1,620,000 |
| 60 lots | 3,000 | HK$ 1,944,000 |
| 70 lots | 3,500 | HK$ 2,268,000 |
| 80 lots | 4,000 | HK$ 2,592,000 |
| 90 lots | 4,500 | HK$ 2,916,000 |
| 100 lots | 5,000 | HK$ 3,240,000 |
| 110 lots | 5,500 | HK$ 3,564,000 |
| 120 lots | 6,000 | HK$ 3,888,000 |
| 130 lots | 6,500 | HK$ 4,212,000 |
| 140 lots | 7,000 | HK$ 4,536,000 |
| 150 lots | 7,500 | HK$ 4,860,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 160 lots | 8,000 | HK$ 5,184,000 |
| 170 lots | 8,500 | HK$ 5,508,000 |
| 180 lots | 9,000 | HK$ 5,832,000 |
| 200 lots | 10,000 | HK$ 6,480,000 |
| 400 lots | 20,000 | HK$ 12,960,000 |
| 600 lots | 30,000 | HK$ 19,440,000 |
| 800 lots | 40,000 | HK$ 25,920,000 |
| 6,000 lots | 300,000 | HK$ 194,400,000 |
| 7,717 lots | 385,850 | HK$ 250,030,800 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 21.04B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 55,688,835,528 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损约195.1百万美元 |
| Period-End Cash Balance | 275.9百万美元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 約164.6百萬美元 |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 129 | 12,985 |
| Cost of sales | -43 | -3,749 |
| Other income and gains, net | 59 | 938 |
| Administrative expenses | -21,576 | -70,211 |
| Operating profit | -141,768 | -203,196 |
| Share of associates and JVs | -587 | -752 |
| Profit before tax | -138,488 | -194,319 |
| Income tax expense | 0 | 0 |
| Profit for the year | -139,075 | -195,071 |
| Profit attributable to owners | -139,075 | -195,071 |
Balance Sheet
| Item | 2018 | 2019 | 2020-06 |
|---|---|---|---|
| Cash and cash equivalents | 62,952 | 75,932 | |
| Trade and bills receivables | 90 | 3,791 | |
| Inventories | 4 | 6,005 | |
| Total current assets | 269,145 | 292,464 | |
| Total assets | 301,987 | 355,153 | |
| Total current liabilities | 48,842 | 46,635 | |
| Total liabilities | 50,906 | 60,493 | |
| Total equity | 251,081 | 294,660 | |
| Interest-bearing borrowings | 3,643 | 6,450 | 4,238 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020-06 |
|---|---|---|---|
| Net cash from operating activities | -97,538 | -191,011 | |
| Net cash from investing activities | -212,554 | -14,892 | |
| Net cash from financing activities | 144,147 | 219,302 | |
| Net increase in cash | -166,708 | 13,490 | |
| Purchase of PP&E | -10,015 | -6,035 | -1,303 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 610.0 |
|---|---|
| First Day Open | HK$ 613.5 |
| First Day Change | 8.54% |
| First Day Volume | 1075520.0 |
| First Day Turnover | 648951000.0 |
| Use of Proceeds | 1、約46.2%預期將分配至我們的核心產品;
2、約11.8%預期將為進行中及計劃臨床試驗以及管線中其他候選藥物(尤其是晚期候選藥物)的準備中注冊備案撥資;
3、約25.0%預期將用于探索新的全球授權及合作機會并引進具有臨床驗證的潛在全球同類最佳/同類首創資產;
4、約7.0%預期將用于持續投資及擴大我們的內部研發產品管線以及在全球招聘及培訓高端人才;
5、約10.0%預期為營運資金及其他一般企業用途撥資。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (4)
Joint Bookrunners (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Citigroup Global Markets Asia Limited CE AAA137
Jefferies Hong Kong Limited CE ATS546
Merrill Lynch (Asia Pacific) Limited CE AAC198
Credit Suisse (Hong Kong) Limited CE AAO017
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Citigroup Global Markets Asia Limited CE AAA137
Jefferies Hong Kong Limited CE ATS546
Merrill Lynch (Asia Pacific) Limited CE AAC198
Credit Suisse (Hong Kong) Limited CE AAO017
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 杜瑩 | — |
| Company Secretary | F.Ty Edmondson | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | QM11 Limited持股12.0%,FMR, LLC持股9.4%,Capital Group持股7.9%,尚珹資本關聯的投資基金持股6.0%,杜瑩博士持股7.8% |
|---|




